1-3 of 3
Paul R Harmatz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety of Combined Chelation Therapy with Deferasirox and Deferoxamine in Transfusion-Dependent Thalassemia.

Ashutosh Lal, MD, Nancy Sweeters, RN, PNP, Matt Herz, Dru Foote, RN, PNP, Lynne Neumayr, MD, Greg Kurio, MD, Paul R Harmatz, MD, Elliott P Vichinsky, MD
Journal: Blood
Blood (2009) 114 (22): 2021.
https://doi.org/10.1182/blood.V114.22.2021.2021
Published: 2009
Journal Articles

Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (Exjade®) Monotherapy in Chronically Transfused β-Thalassemia (β-Thal) Patients: 18- and 24-Month Data.

John C. Wood, Alexis A. Thompson, Carole Paley, Tara Glynos, Barinder Kang, Patricia J. Giardina, Paul R. Harmatz, Thomas Coates
Journal: Blood
Blood (2009) 114 (22): 4069.
https://doi.org/10.1182/blood.V114.22.4069.4069
Published: 2009
Journal Articles

Iron Overload Diminishes the Effectiveness of the Innate Immune Response in Thalassemia Major: a Possible Mechanism for Increased Infection Risk.

Patrick B Walter, PhD, Paul R Harmatz, Annie Higa, B.S., David Killilea, PhD, Nancy Sweeters, RN, PNP, Elliott P Vichinsky, MD
Journal: Blood
Blood (2009) 114 (22): 4071.
https://doi.org/10.1182/blood.V114.22.4071.4071
Published: 2009